Drug Trial Radar · NCT07682870
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Nov 11, 2026
Primary completion
Dec 2, 2028
Study completion Sep 3, 2029
Sponsor
- Lead sponsor
- Virogin Biotech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2025, and recommended dose of VG2025 for Phase II trials.
Conditions
- Advanced Malignant Solid Tumor
Interventions
Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 InjectionDrug
1. Dose level 1 2. Dose level 2 3. Dose level 3 4. Dose level 4 5. Dose level 5 6. Dose level 6 7. Dose level 7
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety:Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 12 months
- MTD/RP2DTime frame: During the 28 day DLT observation period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.